82804-040-30 (Tadalafil 5 mg 30s)
Tadalafil Tablet, Film Coated
Product Images NDC 82804-040
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 82804-040). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Tadalafil-figure-1 (Tadalafil Figure 1)
Standing systolic blood pressure decreased by 10 mmHg with Tadalafil compared to the placebo. Standing diastolic blood pressure remained unchanged. Supine systolic blood pressure decreased by 2 mmHg with Tadalafil compared to the placebo. Supine diastolic blood pressure also remained unchanged. The changes in blood pressure were observed over a period of time, but the exact duration is not available.*
Tadalafil-figure-2 (Tadalafil Figure 2)
Tadalafil-figure-3 (Tadalafil Figure 3)
Tadalafil-figure-4 (Tadalafil Figure 4)
Tadalafil-figure-5 (Tadalafil Figure 5)
Tadalafil-figure-6 (Tadalafil Figure 6)
Tadalafil-figure-7 (Tadalafil Figure 7)
LS Mean Change from Baseline over different weeks of therapy is provided in the text. The values -2.0, -3.0, -4.0, -5.0, -6.0 indicate the least-squares treatment difference. The treatment involves TadalafilFinasteride and Placebo/Finasteride. The text suggests that there are significant treatment effects with p<0.001 for some weeks and p<0.05 for other weeks.*
Tadalafil-figure-8 (Tadalafil Figure 8)
Tadalafil-structure (Tadalafil Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
